Incannex Healthcare Inc. (IXHL) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
8 CENTURY CIRCUIT NORWEST NSW, 2153 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 MRQ | 6/30/2024 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 2,098 | 5,858 | |||
| Cash and cash equivalent | 2,098 | 5,858 | |||
| Receivables | 6,606 | 9,837 | |||
| Prepaid expense | 174 | 329 | |||
| Other undisclosed current assets | 1,626 | 178 | |||
| Total current assets: | 10,504 | 16,202 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 329 | 373 | |||
| Property, plant and equipment | 273 | 472 | |||
| Total noncurrent assets: | 602 | 845 | |||
| TOTAL ASSETS: | 11,106 | 17,047 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 3,884 | 5,457 | |||
| Accounts payable | 818 | 612 | |||
| Accrued liabilities | 3,066 | 4,512 | |||
| Other undisclosed accounts payable and accrued liabilities | 333 | ||||
| Deferred revenue | 27 | ||||
| Debt | 1,383 | ||||
| Other undisclosed current liabilities | 546 | 163 | |||
| Total current liabilities: | 5,840 | 5,620 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 2,385 | ||||
| Long-term debt, excluding current maturities | 2,385 | ||||
| Liabilities, other than long-term debt | 152 | 210 | |||
| Operating lease, liability | 152 | 210 | |||
| Other undisclosed noncurrent liabilities | 1,764 | ||||
| Total noncurrent liabilities: | 4,301 | 210 | |||
| Total liabilities: | 10,141 | 5,830 | |||
| Equity | |||||
| Equity, attributable to parent | 965 | 11,217 | |||
| Common stock | 2 | 2 | |||
| Additional paid in capital | 126,354 | 125,218 | |||
| Accumulated other comprehensive loss | (3,407) | (3,332) | |||
| Accumulated deficit | (121,984) | (110,671) | |||
| Total equity: | 965 | 11,217 | |||
| TOTAL LIABILITIES AND EQUITY: | 11,106 | 17,047 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | ||
|---|---|---|---|---|
| Revenues | (4,902) | 12 | ||
| Other income | 10,800 | |||
| Cost of revenue (Cost of Product and Service Sold) | (0) | |||
| Other undisclosed gross profit | 0 | |||
| Gross profit: | (4,902) | 12 | ||
| Operating expenses | (28,515) | (30,053) | ||
| Other undisclosed operating income | 5,000 | |||
| Operating loss: | (28,417) | (30,041) | ||
| Nonoperating income | 4,641 | 11,612 | ||
| Loss on contract termination | (1,095) | |||
| Interest and debt expense | (171) | |||
| Loss from continuing operations before equity method investments, income taxes: | (23,947) | (18,429) | ||
| Other undisclosed income from continuing operations before income taxes | 171 | |||
| Loss from continuing operations before income taxes: | (23,776) | (18,429) | ||
| Income tax expense | (30) | |||
| Other undisclosed loss from continuing operations | (30) | |||
| Net loss available to common stockholders, diluted: | (23,806) | (18,459) | ||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | ||
|---|---|---|---|---|
| Net loss: | (23,806) | (18,459) | ||
| Comprehensive loss: | (23,806) | (18,459) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (569) | (77) | ||
| Comprehensive loss, net of tax, attributable to parent: | (24,375) | (18,536) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.